Roche says late-stage divarasib study beat Lumakras and Krazati in lung cancer

The Swiss drugmaker said its experimental treatment met primary and key secondary goals in a head-to-head trial involving previously treated patients with a type of advanced lung cancer.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.